Yahoo Finance Bristol-Myers Squibb (BMY) Stock Moves -1.58%: What You Should Know
Bristol-Myers Squibb (BMY) closed the most recent trading day at $54.86, moving -1.58% from the previous trading session. This change was narrower than the S&P 500's 4.41% loss on the day. At the same time, the Dow lost 4.44%, and the tech-heavy Nasdaq lost 4.41%.
Prior to today's trading, shares of the biopharmaceutical company had lost 5.84% over the past month. This has lagged the Medical sector's loss of 5.27% and was narrower than the S&P 500's loss of 12.16% in that time.
BMY will be looking to display strength as it nears its next earnings release, which is expected to be May 7, 2020. The company is expected to report EPS of $1.35, up 22.73% from the prior-year quarter. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $9.92 billion, up 67.59% from the year-ago period.
BMY's full-year Zacks Consensus Estimates are calling for earnings of $6.14 per share and revenue of $41.78 billion. These results would represent year-over-year changes of +30.92% and +59.79%, respectively.
It is also important to note the recent changes to analyst estimates for BMY. These revisions help to show the ever-changing nature of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.03% higher. BMY is currently a Zacks Rank #2 (Buy).
Digging into valuation, BMY currently has a Forward P/E ratio of 9.08. This valuation marks a discount compared to its industry's average Forward P/E of 13.06.
Meanwhile, BMY's PEG ratio is currently 1.23. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. BMY's industry had an average PEG ratio of 1.73 as of yesterday's close.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This group has a Zacks Industry Rank of 21, putting it in the top 9% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Bristol-Myers Squibb Company (BMY) : Free Stock Analysis Report
To read this article on Zacks.com click here.
